Home » Stocks » RCKT

Rocket Pharmaceuticals, Inc. (RCKT)

Stock Price: $55.58 USD 3.72 (7.17%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 3.37B
Revenue (ttm) n/a
Net Income (ttm) -98.64M
Shares Out 55.19M
EPS (ttm) -2.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $55.58
Previous Close $51.86
Change ($) 3.72
Change (%) 7.17%
Day's Open 51.94
Day's Range 50.04 - 56.34
Day's Volume 490,053
52-Week Range 9.01 - 67.48

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
CNBC Television - 3 weeks ago

Reddit playing a major role in biotech trading action, says Jefferies top health care analyst

Jared Holz, Jefferies managing director and healthcare sector specialist, on which biotech stocks could be the next targets. With Melissa Lee and the Fast Money traders, Guy Adami, Tim Seymour...

Other stocks mentioned: KPTI, MDGL
Business Wire - 1 month ago

CRANBURY, N.J.--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therap...

Business Wire - 1 month ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic t...

Zacks Investment Research - 2 months ago

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

Other stocks mentioned: CRSP, DNLI, MCRB, NK
Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic t...

Zacks Investment Research - 2 months ago

Rocket Pharmaceuticals' (RCKT) AAV-based gene therapy candidate demonstrates early evidence of clinical benefit and tolerability in patients with Danon disease, which affects the cardiac muscle.

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic t...

The Motley Fool - 2 months ago

You don't have to be a pandemic fighter to have a big victory for investors.

Other stocks mentioned: GLSI
Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic t...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #Danon--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapi...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #ASH2020--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic thera...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #ASH2020--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic thera...

Business Wire - 2 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic t...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare child...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic t...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic t...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic t...

Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #ESID--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapie...

Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic t...

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #Danon--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapi...

Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic t...

Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for ...

Business Wire - 6 months ago

NEW YORK--(BUSINESS WIRE)---- $RCKT #GeneTherapy--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic t...

Business Wire - 7 months ago

NEW YORK--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare child...

Business Wire - 7 months ago

NEW YORK--(BUSINESS WIRE)-- #IMO--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rar...

Seeking Alpha - 9 months ago

Rocket Pharmaceuticals: Updating Our Bullish View For Recent Events - Still A BUY

Zacks Investment Research - 10 months ago

Rocket Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 11 months ago

Rocket (RCKT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 1 year ago

Does Rocket Pharmaceuticals (RCKT) have what it takes to be a top stock pick for momentum investors? Let's find out.

The Motley Fool - 1 year ago

The remaining weeks of December are chock-full of clinical trial results and FDA approval decisions that savvy investors can take advantage of.

Other stocks mentioned: AGN, ALEC, AMRN, ATNX, BHVN, CARA, GBT, ITCI, NVS, PBYI, PTGX, PTI
Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Rocket Pharmaceuticals, Inc. (RCKT).

Seeking Alpha - 1 year ago

RCKT has solid pipeline assets and plenty of catalysts during next 12 months for value creation. There are no near-term funding needs.

Seeking Alpha - 1 year ago

Rocket Therapeutics has remained under my radar despite making headway in the gene therapy pipeline with multiple INDs being accepted. I review the companies technology and pipeline candidates.

About RCKT

Rocket Pharmaceuticals, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction, and pyruvate kinase deficiency... [Read more...]

Industry
Biotechnology
CEO
Gaurav Shah
Employees
84
Stock Exchange
NASDAQ
Ticker Symbol
RCKT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for RCKT stock is "Strong Buy." The 12-month stock price forecast is 72.64, which is an increase of 30.69% from the latest price.

Price Target
$72.64
(30.69% upside)
Analyst Consensus: Strong Buy